AtriCure prices latest offering; Cambridge Heart winds down operations;

@FierceMedDev: Illumina's Jay Flatley brought sequencing to another level in 2013--the $1000 genome is now a reality. Report | Follow @FierceMedDev

@MarkHFierce: Amedica's IPO is going steadily. Stock at $6.19 as of 10:56 A.M. Moderately higher. Story | Follow @MarkHFierce

@MichaelGFierce: CalTech engineers have created an antibody carrier that could prevent intravaginal HIV infection. Not a vaccine... More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: "Musical hallucinations" give scientists clues about brain function, hearing loss. Article | Follow @EmilyWFierce

> AtriCure ($ATRC) has priced its previously announced underwritten public offering. The atrial fibrillation medical device company, along with selling stockholders, plans to offer 4.2 million shares of common stock at $19.25 per share. Item

> Spain's Neuroelectrics, a maker of neurostimulation and brain monitoring devices, has opened its first U.S. office at the Cambridge Innovation Center in Cambridge, MA. Item 

> Cardiac diagnostics maker Cambridge Heart ($CAMH) is winding down operations and has auctioned off assets to pay creditors. Story

> A fast-moving winter storm forced the cancelation of Staar Surgical's ($STAA) meeting before the FDA Ophthalmic Devices Panel, which had been scheduled for Feb. 14. Staar is seeking a PMA supplement approval for its Visian Toric Implantable Collamer Lens. Item

> Diagnostic test-kit developer Corgenix Medical said that its revenue and net income increased during its fiscal 2014 second quarter. Item

> Scotland's Calcivis, a medical device company focused on tooth decay, won a CE mark for an imaging system designed to perform ultra-precise detection of tooth decay. Item

Biotech News

@FierceBiotech: Like him or not, Myriad Genetics' Peter Meldrum helped make predictive cancer testing viable. Profile | Follow @FierceBiotech

@JohnCFierce: Who's influential in biopharma? (ICYMI) Report | Follow @JohnCFierce

@DamianFierce: FDA rejects Durect's pitch to market post-operative pain therapy. More | Follow @DamianFierce

@EmilyMFierce: GlaxoSmithKline joins $115M antibiotics development initiative. Story via FierceBiotech Research | Follow @EmilyMFierce

> Novartis CEO Jimenez looking for new places to hatchet blockbuster R&D budget. News

> Biotech IPOs roll on with Concert's $84M aria. Article

> FDA panel pillories The Medicines Co.'s clot-fighting cangrelor. More

Pharma News

@FiercePharma: More than 2,000 Pradaxa patients are suing Boehringer over severe or fatal bleeding. More | Follow @FiercePharma

@TracyStaton: Our best-read feature every year: The most influential people in biopharma today. Report | Follow @TracyStaton

@EricPFierce: It's 1 thing for an API seller to have poor quality controls, but FDA says it's a real problem to have none. Story | Follow @EricPFierce

@CarlyHFierce: Merck consumer-health deal heats up with $10B-plus bids expected soon. News | Follow @CarlyHFierce

> Antitrust watchdogs come down on Pfizer for Lipitor dealmaking. Story

> Boehringer says it's fighting 2,000 lawsuits over Pradaxa safety. Article

> Merck consumer-health deal heats up with $10B-plus bids expected soon. News

Pharma Manufacturing News

> Congress wants more info about the quality of foreign-made generics. Story

> 2 Hospira plants improve their FDA standing as improvements kick in. Article

> Irish Regeneron plant to produce tax benefits as well as drugs. Story

> Catalent to expand in U.S. and add 230 jobs to its Kansas City operation. News

> The FDA slams a Hong Kong API for the sorry state of its quality controls. Story

> New plants in Middle East are a testament to the region's emerging market status. Item

Vaccines News

> Quadrivalent flu vaccines drive surge in sales at AstraZeneca, GSK and Sanofi. Earnings

> The President's Cancer Panel is pushing for increased use of Merck's and GSK's HPV vaccines. News

> Crowdfunded HIV project draws criticism from scientists. Story

> CDC: Adult vaccination rates are still well below targets. Article

> The U.S. flu season is slowly winding down after hitting some states hard. Story

> Global measles deaths have dropped 78% since 2000. Brief

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.